Since either metformin or GLP-1 analogue has vascular protective effects 7,24 , we reasonably hypothesized that this combination therapy might also have a synergistic protective effect on endothelial function
MIDI Health is charging $250 cash for a 30 minute new patient appointment for those without insurance, and its likely they are getting less than $200 (maybe $150-170) from insurance
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
Sometimes, vitamin deficiencies go undiagnosed, causing a doctor to be unsure of the reason why a patient is experiencing certain symptoms
In this study, we investigated the contribution of intestinal glucose handling to metformins systemic metabolic effects
Most failures in peptide protocols for chronic conditions aren't the peptide
